These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10328990)

  • 1. New vs old fashioned oestradiol antagonists in mammary carcinoma: 'in vitro' and 'in vivo' pharmacological approaches.
    de Cupis A; Schettini G; Favoni RE
    Pharmacol Res; 1999 May; 39(5):335-44. PubMed ID: 10328990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The elucidation of the antiestrogen and antitumoral mechanisms of tamoxifen].
    Borgna JL
    Bull Cancer; 1994 Jan; 81(1):29-37. PubMed ID: 7949581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal.
    Favoni RE; de Cupis A
    Trends Pharmacol Sci; 1998 Oct; 19(10):406-15. PubMed ID: 9803831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects and mechanism of action of antiestrogens in breast cancer].
    Borgna JL; Rochefort H
    Pathol Biol (Paris); 1983 Nov; 31(9):775-81. PubMed ID: 6361675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antioestrogens.
    de Cupis A; Favoni RE
    Trends Pharmacol Sci; 1997 Jul; 18(7):245-51. PubMed ID: 9253856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antiestrogens].
    Saez S
    Presse Med; 1984 May; 13(20):1261-5. PubMed ID: 6232584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of tamoxifen resistance.
    Ring A; Dowsett M
    Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships.
    Allen KE; Clark ER; Jordan VC
    Br J Pharmacol; 1980; 71(1):83-91. PubMed ID: 7470748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
    Jordan VC
    Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Searching for the ideal SERM.
    Poletti A
    Pharmacol Res; 1999 May; 39(5):333. PubMed ID: 10328989
    [No Abstract]   [Full Text] [Related]  

  • 14. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Action of SERM and SAS (tibolone) on breast tissue].
    Gompel A; Jacob D; de Chambine S; Mimoun M; Decroix Y; Rostene W; Poitout P
    Contracept Fertil Sex; 1999 May; 27(5):368-75. PubMed ID: 10401183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological rationale for endocrine therapy in breast cancer.
    Miller WR
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):1-32. PubMed ID: 14687595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens.
    Wakeling AE; Valcaccia B
    J Endocrinol; 1983 Dec; 99(3):455-64. PubMed ID: 6644236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen ("Nolvadex"): a review.
    Clemons M; Danson S; Howell A
    Cancer Treat Rev; 2002 Aug; 28(4):165-80. PubMed ID: 12363457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.